Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Bicycle Therapeutics Plc ADR shares valued at $4,831 were sold by Hannay Michael Charles Ferguso on Jul 03 ’24. At $19.64 per share, Hannay Michael Charles Ferguso sold 246 shares. The insider’s holdings dropped to 22,645 shares worth approximately $0.58 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Skynner Michael sold 967 shares, netting a total of over 18,992 in proceeds. Following the sale of shares at $19.64 each, the insider now holds 93,917 shares.
Before that, Thompson Travis Alvin had sold 148 shares from its account. In a trade valued at $2,907, the CHIEF ACCOUNTING OFFICER traded Bicycle Therapeutics Plc ADR shares for $19.64 each. Upon closing the transaction, the insider’s holdings decreased to 148 shares, worth approximately $0.59 million.
As published in their initiating research note from RBC Capital Mkts on September 06, 2024, Bicycle Therapeutics Plc ADR [BCYC] has been an Outperform and the price target has been revised to $35. Analysts at B. Riley Securities downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in early August. As of September 11, 2023, B. Riley Securities has increased its “Neutral” rating to a “Buy” for BCYC. Earlier on August 31, 2022, Cowen initiated its rating. Their recommendation was “an Outperform” for BCYC stock.
Analyzing BCYC Stock Performance
During the last five days, there has been a drop of approximately -6.39%. Over the course of the year, Bicycle Therapeutics Plc ADR shares have jumped approximately 41.04%. Shares of the company reached a 52-week high of $28.20 on 09/12/24 and a 52-week low of $16.13 on 01/05/24. A 50-day SMA is recorded $23.39, while a 200-day SMA reached $21.76. Nevertheless, trading volume fell to 0.43 million shares from 0.22 million shares the previous day.
Support And Resistance Levels for Bicycle Therapeutics Plc ADR (BCYC)
According to the 24-hour chart, there is a support level at 24.60, which, if violated, would cause prices to drop to 23.70. In the upper region, resistance lies at 26.08. The next price resistance is at 26.67. RSI (Relative Strength Index) is 58.53 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.63, which suggests the price will decrease in the coming days. Percent R is at 33.01%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
